Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1969 1
1987 1
1993 1
1994 1
1995 2
1996 1
1997 1
1998 1
1999 2
2000 2
2001 1
2003 2
2004 3
2005 2
2008 1
2010 3
2011 5
2012 3
2013 1
2014 5
2015 3
2016 5
2017 4
2018 4
2019 4
2020 10
2021 8
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors.
Herpers B, Eppink B, James MI, Cortina C, Cañellas-Socias A, Boj SF, Hernando-Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink-Clements C, Zondag-van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ramírez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan-Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M. Herpers B, et al. Among authors: price ls. Nat Cancer. 2022 Apr;3(4):418-436. doi: 10.1038/s43018-022-00359-0. Epub 2022 Apr 25. Nat Cancer. 2022. PMID: 35469014 Free article.
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
Duke ES, Bradford D, Marcovitz M, Amatya AK, Mishra-Kalyani PS, Nguyen E, Price LSL, Fourie Zirkelbach J, Li Y, Bi Y, Kraft J, Dorff SE, Scepura B, Stephenson M, Ojofeitimi I, Nair A, Han Y, Tezak Z, Lemery SJ, Pazdur R, Larkins E, Singh H. Duke ES, et al. Among authors: price lsl. Clin Cancer Res. 2023 Sep 15;29(18):3573-3578. doi: 10.1158/1078-0432.CCR-23-0459. Clin Cancer Res. 2023. PMID: 37265412 Free PMC article. Clinical Trial.
Factors Affecting the Pharmacology of Antibody-Drug Conjugates.
Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, Zamboni WC. Lucas AT, et al. Among authors: price lsl. Antibodies (Basel). 2018 Feb 7;7(1):10. doi: 10.3390/antib7010010. Antibodies (Basel). 2018. PMID: 31544862 Free PMC article. Review.
Screening out irrelevant cell-based models of disease.
Horvath P, Aulner N, Bickle M, Davies AM, Nery ED, Ebner D, Montoya MC, Östling P, Pietiäinen V, Price LS, Shorte SL, Turcatti G, von Schantz C, Carragher NO. Horvath P, et al. Among authors: price ls. Nat Rev Drug Discov. 2016 Nov;15(11):751-769. doi: 10.1038/nrd.2016.175. Epub 2016 Sep 12. Nat Rev Drug Discov. 2016. PMID: 27616293 Review.
Rho family proteins in cell adhesion and cell migration.
Evers EE, Zondag GC, Malliri A, Price LS, ten Klooster JP, van der Kammen RA, Collard JG. Evers EE, et al. Among authors: price ls. Eur J Cancer. 2000 Jun;36(10):1269-74. doi: 10.1016/s0959-8049(00)00091-5. Eur J Cancer. 2000. PMID: 10882865 Review.
78 results